Under the SC Proven brand, both the companies have launched the first product, ultra-primary human fibroblast cell line, which are believed to be starting material to generate human iPS cell lines by genetic reprogramming.
StemCells development and operations Stewart Craig senior vice president said the scientists at R Biomedical are experts in the development of reagents for the iPS cell field and has secured ethical approval to collect and process human somatic cells expressly designed for generating iPS cell lines.
"We are pleased to collaborate with R Biomedical for the commercialization of a series of new and innovative products to enable regenerative medicine research," Craig added.
R Biomedical Joe Mee managing director said, "R Biomedical is extremely well positioned to provide unique iPS cell reagents, accompanying technology and culture reagents to both academic and industrial researchers in partnership with StemCells under their globally recognized and distributed SC Proven brand."